24. A composition according to any one of claims 20 to 23, wherein the modified release is a delayed release.

25. A composition according to claim 24, wherein the composition is in the form of an enteric tablet formulation.

26. A composition according to claim 25, wherein the enteric coated tablet is a single layer tablet.

27. A composition according to claim 25, wherein the enteric coated tablet is a multi-layer tablet.

A1 cont

28. A composition according to any one of claims 25 to 27, wherein the tablet is coated with a gastric resistant polymer.

29. A composition according to claim 28, wherein the gastric resistant polymer is selected from the list consisting of Eudragit L100-55, methacrylates, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phtahlate.

30. A composition according to claim 28 wherein the gastric resistant polymer is selected from the group consisting of Aquateric, Sureteric and HPMCP-HP-555.

31. A composition according to any one of claims 20 to 23, wherein the modified release is a sustained release.

32. A composition according to claim 31, wherein the sustained release is provided by a sustained release matrix selected from the group of matrices consisting of: disintegrating, non- disintegrating and eroding matrices.

33. A composition according to claim 32, wherein the non-disintegrating matrix tablet formulation is provided by incorporating ~~one~~ or more members of the group consisting of: Eudragit RS, methacrylates, cellulose acetates, hydroxypropyl methylcellulose phthalate, Carbopol 971P or HPMCP-HP-55S into the matrix.

34. A composition according to claim 32, wherein the disintegrating matrix tablet formulation is provided by incorporating one or more members of the group consisting of: methacrylates, methylcellulose and Methocel K4M into the matrix.

35. A composition according to any one of claims 20 to 23, wherein the insulin sensitiser is selected from the group consisting of: 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (pioglitazone) and (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone);
or a derivative thereof.

36. A composition according to any one of claims 20 to 23 wherein the other antidiabetic agent is selected from the group consisting of: an alpha glucosidase inhibitor, a biguanide, and an insulin secretagogue.

Cl cont.

37. A composition according to claim 36, wherein the alpha glucosidase inhibitor is selected from the group consisting of: acarbose, emiglitate, miglitol and voglibose.

38. A composition according to claim 36, wherein the biguanide is selected from the group consisting of: metformin, buformin and phenformin.

39. A composition according to claim 36, wherein the insulin secretagogue is a sulphonylurea selected from the group consisting of: glibenclamide, glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide, glycylamide and glipentide.

40. A composition according to claim 36, wherein the insulin secretagogue is selected from the group consisting of: repaglinide and nateglinide.